Model development and medical counter measures (mcms) for BSL-4 agents in nhps.
Active Awarded Last action
- Contract number
- 75N93024F00002
- Awardee
-
University Of Texas Medical Branch At Galveston UEI MSPWVMXXMN76
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,270,971
Award facts
- Contract value 49% obligated
-
- $3,270,971.00 Current, with exercised options
- $6,739,837.00 Potential, with all options
- Completion date 78% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Galveston, TX 77555, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $1,660,462 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,610,509 |
About this award
The National Institute of Allergy and Infectious Diseases issued a $6.74 million delivery order to the University of Texas Medical Branch at Galveston on June 25, 2024, under the NIAID Preclinical Models of Infectious Diseases 2017–2024 indefinite delivery vehicle for development of medical countermeasures and animal models for biosafety level 4 agents in non-human primates.
The order is priced on a cost, no-fee basis with a ceiling value of $6.74 million and an ultimate completion date of June 24, 2027. Place of performance is Galveston, TX. The work encompasses model development and preclinical research supporting evaluation of medical countermeasures against high-consequence biological pathogens, leveraging UTMB's specialized capabilities in high-containment laboratory environments and non-human primate infectious disease research.
Quick answers
Who was awarded contract 75N93024F00002?
75N93024F00002 was awarded to University Of Texas Medical Branch At Galveston by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 25, 2024.
How much is contract 75N93024F00002 worth?
The government has obligated $3,270,971 on 75N93024F00002. Its potential value, with all options, is $6,739,837.
Is contract 75N93024F00002 an order under another contract?
Yes. 75N93024F00002 is a delivery order under HHSN272201700040I, an indefinite delivery contract, on NIAID Preclinical Models of Infectious Diseases 2017-2024.
Was contract 75N93024F00002 competed?
The extent of competition for 75N93024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award